vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and CASEYS GENERAL STORES INC (CASY). Click either name above to swap in a different company.
CASEYS GENERAL STORES INC is the larger business by last-quarter revenue ($4.5B vs $2.8B, roughly 1.6× Bausch Health Companies Inc.). CASEYS GENERAL STORES INC runs the higher net margin — 4.6% vs -3.7%, a 8.3% gap on every dollar of revenue. On growth, CASEYS GENERAL STORES INC posted the faster year-over-year revenue change (14.2% vs 9.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $176.0M). Over the past eight quarters, CASEYS GENERAL STORES INC's revenue compounded faster (16.3% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Casey's Retail Company is a chain of convenience stores in the Midwestern and Southern United States. The company is headquartered in Ankeny, Iowa, a suburb of Des Moines. As of October 1, 2023, Casey's had 2,500 stores in 16 states. Following 7-Eleven's purchase of Speedway, Casey's is the third-largest convenience store chain in the United States and the largest that is wholly American-owned. It is one of two Iowa-based Fortune 500 companies. Casey's is famous for their pizza, including a b...
BHC vs CASY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $4.5B |
| Net Profit | $-103.0M | $206.3M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 6.1% |
| Net Margin | -3.7% | 4.6% |
| Revenue YoY | 9.3% | 14.2% |
| Net Profit YoY | -205.1% | 14.0% |
| EPS (diluted) | $-0.30 | $5.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $4.5B | ||
| Q3 25 | $2.7B | $4.6B | ||
| Q2 25 | $2.5B | $4.0B | ||
| Q1 25 | $2.3B | $3.9B | ||
| Q4 24 | $2.6B | $3.9B | ||
| Q3 24 | $2.5B | $4.1B | ||
| Q2 24 | $2.4B | $3.6B | ||
| Q1 24 | $2.2B | $3.3B |
| Q4 25 | $-103.0M | $206.3M | ||
| Q3 25 | $179.0M | $215.4M | ||
| Q2 25 | $148.0M | $98.3M | ||
| Q1 25 | $-58.0M | $87.1M | ||
| Q4 24 | $98.0M | $180.9M | ||
| Q3 24 | $-85.0M | $180.2M | ||
| Q2 24 | $10.0M | $87.0M | ||
| Q1 24 | $-64.0M | $86.9M |
| Q4 25 | 17.0% | 6.1% | ||
| Q3 25 | 23.1% | 6.1% | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 12.2% | 2.8% | ||
| Q4 24 | 21.8% | 6.1% | ||
| Q3 24 | 12.7% | 5.8% | ||
| Q2 24 | 16.2% | — | ||
| Q1 24 | 13.1% | 3.4% |
| Q4 25 | -3.7% | 4.6% | ||
| Q3 25 | 6.7% | 4.7% | ||
| Q2 25 | 5.8% | 2.5% | ||
| Q1 25 | -2.6% | 2.2% | ||
| Q4 24 | 3.8% | 4.6% | ||
| Q3 24 | -3.4% | 4.4% | ||
| Q2 24 | 0.4% | 2.4% | ||
| Q1 24 | -3.0% | 2.6% |
| Q4 25 | $-0.30 | $5.53 | ||
| Q3 25 | $0.48 | $5.77 | ||
| Q2 25 | $0.40 | $2.63 | ||
| Q1 25 | $-0.16 | $2.33 | ||
| Q4 24 | $0.24 | $4.85 | ||
| Q3 24 | $-0.23 | $4.83 | ||
| Q2 24 | $0.03 | $2.34 | ||
| Q1 24 | $-0.17 | $2.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $492.0M |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $3.8B |
| Total Assets | $26.4B | $8.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $492.0M | ||
| Q3 25 | $1.3B | $458.1M | ||
| Q2 25 | $1.7B | $326.7M | ||
| Q1 25 | $1.1B | $394.8M | ||
| Q4 24 | $1.2B | $351.7M | ||
| Q3 24 | $719.0M | $305.0M | ||
| Q2 24 | $595.0M | $206.5M | ||
| Q1 24 | $733.0M | $177.9M |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | $2.4B | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | $1.6B | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $3.8B | ||
| Q3 25 | $-565.0M | $3.6B | ||
| Q2 25 | $-764.0M | $3.5B | ||
| Q1 25 | $-1.2B | $3.4B | ||
| Q4 24 | $-1.3B | $3.3B | ||
| Q3 24 | $-1.2B | $3.2B | ||
| Q2 24 | $-1.2B | $3.0B | ||
| Q1 24 | $-1.1B | $2.9B |
| Q4 25 | $26.4B | $8.6B | ||
| Q3 25 | $26.8B | $8.4B | ||
| Q2 25 | $27.3B | $8.2B | ||
| Q1 25 | $26.4B | $8.2B | ||
| Q4 24 | $26.5B | $7.7B | ||
| Q3 24 | $26.5B | $6.5B | ||
| Q2 24 | $26.5B | $6.3B | ||
| Q1 24 | $26.9B | $6.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $347.1M |
| Free Cash FlowOCF − Capex | $403.0M | $176.0M |
| FCF MarginFCF / Revenue | 14.4% | 3.9% |
| Capex IntensityCapex / Revenue | 3.3% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $682.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $347.1M | ||
| Q3 25 | $405.0M | $372.4M | ||
| Q2 25 | $289.0M | $333.9M | ||
| Q1 25 | $211.0M | $204.9M | ||
| Q4 24 | $601.0M | $270.7M | ||
| Q3 24 | $405.0M | $281.4M | ||
| Q2 24 | $380.0M | $288.4M | ||
| Q1 24 | $211.0M | $122.8M |
| Q4 25 | $403.0M | $176.0M | ||
| Q3 25 | $314.0M | $262.4M | ||
| Q2 25 | $190.0M | $153.1M | ||
| Q1 25 | $96.0M | $90.7M | ||
| Q4 24 | $495.0M | $160.0M | ||
| Q3 24 | $334.0M | $180.8M | ||
| Q2 24 | $302.0M | $92.1M | ||
| Q1 24 | $129.0M | $-27.0M |
| Q4 25 | 14.4% | 3.9% | ||
| Q3 25 | 11.7% | 5.7% | ||
| Q2 25 | 7.5% | 3.8% | ||
| Q1 25 | 4.2% | 2.3% | ||
| Q4 24 | 19.3% | 4.1% | ||
| Q3 24 | 13.3% | 4.4% | ||
| Q2 24 | 12.6% | 2.6% | ||
| Q1 24 | 6.0% | -0.8% |
| Q4 25 | 3.3% | 3.8% | ||
| Q3 25 | 3.4% | 2.4% | ||
| Q2 25 | 3.9% | 4.5% | ||
| Q1 25 | 5.1% | 2.9% | ||
| Q4 24 | 4.1% | 2.8% | ||
| Q3 24 | 2.8% | 2.5% | ||
| Q2 24 | 3.2% | 5.5% | ||
| Q1 24 | 3.8% | 4.5% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 2.26× | 1.73× | ||
| Q2 25 | 1.95× | 3.40× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | 6.13× | 1.50× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | 38.00× | 3.31× | ||
| Q1 24 | — | 1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
CASY
Segment breakdown not available.
